NEW YORK (GenomeWeb) – Ncardia said today that it has entered into a non-exclusive global intellectual property licensing agreement with Evotec, which gives Evotec access to patented technology and methods for stem cell-derived modeling for target discovery, drug efficacy, and safety testing.
Ncardia has developed a variety of predictive human cellular assays systems, including a broad panel of induced pluripotent stem cell (iPSC)-derived lines of both cardiac cells and neurons.